Please use this identifier to cite or link to this item:
Title: Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
Austin Authors: Tebbutt, Niall C ;Murphy, F;Zannino, D;Wilson, K;Cummins, M M;Abdi, E;Strickland, A H;Lowenthal, R M;Marx, G;Karapetis, C;Shannon, J;Goldstein, David B;Nayagam, S S;Blum, R;Chantrill, L;Simes, R J;Price, Timothy J
Institutional Author: Australasian Gastro-Intestinal Trials Group
Department of Medical Oncology, Austin Health, Melbourne, Australia
Issue Date: 27-Jan-2011
Publication information: Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo 2011; 22(8): 1834-8
Abstract: Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab.We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patients with metastatic colorectal cancer in the MAX (Mitomycin, Avastin, Xeloda) trial of capecitabine monotherapy versus capecitabine with bevacizumab with or without mitomycin C.Bevacizumab-treated patients had 12 grade 3, 4, or 5 ATEs (3.8% incidence). ATEs occurred in 2.1% of patients >65 years, 5% of those with a history of ATE, and 5% of those with cardiac risk factors. Age, history of ATE, or vascular risk factors did not increase risk. Aspirin users had a higher incidence than nonusers (8.9% versus 2.7%) but had higher rates of vascular risk factors.Bevacizumab was associated with a modestly higher risk of ATE, but safety was not significantly worse in older patients or patients with a history of ATE or vascular risk factors. The effect of aspirin in preventing ATE in patients receiving bevacizumab could not be determined from this study.
Gov't Doc #: 21273347
DOI: 10.1093/annonc/mdq702
Journal: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Type: Journal Article
Subjects: Adult
Age Factors
Aged, 80 and over
Angiogenesis Inhibitors.adverse effects.therapeutic use
Antibodies, Monoclonal, Humanized.adverse effects.therapeutic use
Aspirin.therapeutic use
Colorectal Neoplasms.drug therapy.pathology
Middle Aged
Neoplasm Staging
Risk Factors
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 25, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.